Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08JBL
|
|||
| Former ID |
DNCL002401
|
|||
| Drug Name |
PF-03446962
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Pfizer New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Activin receptor-like kinase-1 (ACVRL1) | Target Info | Modulator | [2] |
| Panther Pathway | TGF-beta signaling pathway | |||
| Pathway Interaction Database | ALK1 pathway | |||
| ALK1 signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01620970) PF-03446962 in Relapsed or Refractory Urothelial Cancer. U.S. National Institutes of Health. | |||
| REF 2 | ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.